David S Reynolds
Overview
Explore the profile of David S Reynolds including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
595
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benn C, Gibson K, Reynolds D
J Huntingtons Dis
. 2020 Sep;
10(1):203-220.
PMID: 32925081
DNA damage repair (DDR) mechanisms have been implicated in a number of neurodegenerative diseases (both genetically determined and sporadic). Consistent with this, recent genome-wide association studies in Huntington's disease (HD)...
2.
Owen R, Blakemore D, Cao L, Flanagan N, Fish R, Gibson K, et al.
J Med Chem
. 2019 Apr;
62(12):5773-5796.
PMID: 30964988
The design, optimization, and evaluation of a series of novel imidazopyridazine-based subtype-selective positive allosteric modulators (PAMs) for the GABA ligand-gated ion channel are described. From a set of initial hits...
3.
Gurrell R, Gorman D, Whitlock M, Ogden A, Reynolds D, DiVentura B, et al.
Neurology
. 2019 Mar;
92(15):e1786-e1795.
PMID: 30877186
Objective: The objective of this phase 2a study was to assess the activity of PF-06372865, a positive allosteric modulator (PAM) of α2/3/5 subunit-containing GABA receptors with minimal activity at α1-containing...
4.
Reynolds D
Br J Pharmacol
. 2019 Jan;
176(18):3636-3648.
PMID: 30657599
Globally, there are approximately 47 million people living with dementia, and about two thirds of those have Alzheimer's disease (AD). Age is the single biggest risk factor for the vast...
5.
Gurrell R, Dua P, Feng G, Sudworth M, Whitlock M, Reynolds D, et al.
Pain
. 2018 May;
159(9):1742-1751.
PMID: 29787472
The effect of PF-06372865, a subtype-selective positive allosteric modulator of the γ-aminobutyric acid type A (GABAA) receptor, on chronic low back pain was investigated in a randomised, placebo- and active-controlled...
6.
Duke A, Meng Z, Platt D, Atack J, Dawson G, Reynolds D, et al.
J Pharmacol Exp Ther
. 2018 May;
366(1):145-157.
PMID: 29720564
In nonhuman primates we tested a new set of behavioral categories for observable sedative effects using pediatric anesthesiology classifications as a basis. Using quantitative behavioral observation techniques in rhesus monkeys,...
7.
Nickolls S, Gurrell R, van Amerongen G, Kammonen J, Cao L, Brown A, et al.
Br J Pharmacol
. 2017 Dec;
175(4):708-725.
PMID: 29214652
Background And Purpose: Benzodiazepines, non-selective positive allosteric modulators (PAMs) of GABA receptors, have significant side effects that limit their clinical utility. As many of these side effects are mediated by...
8.
Winchester W, Gore K, Glatt S, Petit W, Gardiner J, Conlon K, et al.
J Pharmacol Exp Ther
. 2014 Aug;
351(2):259-69.
PMID: 25125580
The transient receptor potential (subfamily M, member 8; TRPM8) is a nonselective cation channel localized in primary sensory neurons, and is a candidate for cold thermosensing, mediation of cold pain,...
9.
Shinday N, Sawyer E, Fischer B, Platt D, Licata S, Atack J, et al.
Neuropsychopharmacology
. 2013 Jan;
38(6):1006-14.
PMID: 23303046
Benzodiazepines are prescribed widely but their utility is limited by unwanted side effects, including abuse potential. The mechanisms underlying the abuse-related effects of benzodiazepines are not well understood, although α1...
10.
Fischer B, Atack J, Platt D, Reynolds D, Dawson G, Rowlett J
Psychopharmacology (Berl)
. 2010 Dec;
215(2):311-9.
PMID: 21190016
Rationale: Experimental evidence suggests that the differential behavioral effects of benzodiazepines depend on their relative actions at γ-aminobutyric acid type A (GABA(A)) receptors that contain either an α1, α2, α3,...